Opinion|Videos|January 30, 2024
Expert Insights on Adjuvant Immunotherapy in Unresectable Stage-III NSCLC
A panel of oncology experts examine the role of consolidation immunotherapy in patients receiving concurrent chemoradiotherapy for unresectable Stage-III NSCLC, discussing 5-year survival outcomes from the PACIFIC trial, the impact on institutional treatment approaches, criteria for selecting patients for consolidation durvalumab, the significance of baseline scans, as well as exploring real-world evidence on consolidation durvalumab.
Advertisement
Episodes in this series
Advertisement
Related to this article
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
Matthew Lee, MD, discusses the first clinical data for BG-C477, a CEACAM5-targeting ADC, in advanced NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Matthew Lee, MD, shares his key takeaway from the first disclosure of BG-C477 data in advanced NSCLC.
Matthew Lee, MD, discusses how confident he is that CEACAM5 expression will hold up as a biomarker for BG-C477 in NSCLC.
In the real-world CEMI-LUNG study, first-line cemiplimab produced survival and response outcomes consistent with the pivotal EMPOWER-Lung 1 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
2
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
3
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?
4
Breast Cancer Locator Noninferior to Wire Localization for Lumpectomy Margins
5